Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2026-03-15 @ 3:15 PM
Study NCT ID:
NCT02655692
Status:
COMPLETED
Last Update Posted:
2022-06-02
First Post:
2016-01-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
CAP-Ketamine for Antidepressant Resistant PTSD
Sponsor:
VA Office of Research and Development
Organization:
Study Overview
Official Title:
CAP-Ketamine for Antidepressant Resistant PTSD
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Detailed Description:
In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of three treatment arms (placebo, low dose ketamine, high dose ketamine). Participants receive the study drug via intravenous infusion twice per week for 4-weeks.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: